Issue Date: Sep 15, 2011
For sheer persistence you have to hand it to Novartis. Ever since its blood cancer drug Glivec was refused a patent in 2006, the Swiss multinational has been fighting India’s patent law, or at least a crucial section of it, with the patent authorities and in the courts. With case now in the Supreme Court, there is a high sense of expectancy— and unease.
Cheryl Colopy‘s book explores how south Asian rivers have been transformed from being considered sacred beings to sewers
How a township has set high standard for eco-friendly living